跳至主要内容
临床试验/NCT00180544
NCT00180544终止3 期

A Prospective, Non-Randomized, Multicenter, Single-Arm, Clinical Trial to Assess the Safety and Efficacy of the RX HERCULINK 14 Peripheral Stent System for Treatment in de Novo or Restenotic Renal Artery Stenosis

Abbott Medical Devices2 个研究点 分布在 1 个国家目标入组 167 人开始时间: 2000年7月最近更新:
适应症

试验速览

阶段
3 期
状态
终止
入组人数
167
试验地点
2
主要终点
Primary patency .

研究概览

简要总结

The purpose of this study is to evaluate the safety and effectiveness of the RX HERCULINK 14 Peripheral Stent System in treating atherosclerotic renal artery stenosis.

详细描述

A prospective, non-randomized, multi-center, single-arm clinical trial to evaluate the safety and efficacy of the RX HERCULINK™ 14 Peripheral Stent System in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) results in de novo or restenotic atherosclerotic renal artery stenoses.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of renal artery atherosclerosis; candidate for renal artery angioplasty and stenting; blood pressure >160/90

排除标准

  • Totally occluded renal artery on the opposite side; only one functioning kidney; target lesion is in a transplanted kidney; renal insufficiency

结局指标

主要结局

Primary patency .

时间窗: at 9-months

次要结局

  • Acute procedural success(Acute)
  • Access site events requiring surgical repair or intervention(Acute)
  • Major adverse events (e.g. death, nephrectomy, target lesion revascularization (TLR)(at 30 days)
  • TLR(at 9 months)
  • Renal function(measured at 1, 6, 9, and 12-month follow-up, and every three months thereafter until approximately May 2003 or until patient 169 completes 12 month follow-up.)
  • Changes in blood pressure(9 months)

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验